Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, PR China.
Med Hypotheses. 2013 Aug;81(2):319-21. doi: 10.1016/j.mehy.2013.04.010. Epub 2013 May 18.
Gliomas are the most malignant and common primary brain tumors, accounting for 50-60%. Despite all surgical efforts in combination with intense chemoradiotherapy, gliomas still have a dismal prognosis. The early screening and identification of patients with gliomas could improve their prognosis by allowing proactive medical treatment. Traditionally, gliomas of varying subtypes and grades are diagnosed based on histopathological features, but this can be challenging, particularly in cases that lack the typical features. Molecular expression profiles using microarray analyses have provided additional information to help distinguish between glioma subtypes, which correlate well with histological profiles. Various molecular biomarkers and therapeutic targets for gliomas are currently available, including genes and miRNAs, but all remain in preclinical studies. Certain specific lncRNAs involved in gliomas have been identified in surgical brain biopsies, which may be involved in brain development and the pathogenesis of gliomas; these can also be detected in peripheral blood. Therefore, we postulate that these specific lncRNAs may be both potential biomarkers and therapeutic targets for gliomas.
神经胶质瘤是最恶性和最常见的原发性脑肿瘤，占 50-60%。尽管所有的手术努力都结合了强化的放化疗，但神经胶质瘤的预后仍然很差。早期筛查和识别神经胶质瘤患者可以通过主动的医疗治疗来改善他们的预后。传统上，不同亚型和分级的神经胶质瘤是基于组织病理学特征来诊断的，但这可能具有挑战性，特别是在缺乏典型特征的情况下。使用微阵列分析的分子表达谱提供了额外的信息，有助于区分神经胶质瘤亚型，这与组织学特征很好地相关。目前有多种用于神经胶质瘤的分子生物标志物和治疗靶点，包括基因和 miRNA，但都仍处于临床前研究阶段。在手术脑活检中已经鉴定出某些特定的与神经胶质瘤相关的 lncRNAs，它们可能参与脑发育和神经胶质瘤的发病机制；这些也可以在外周血中检测到。因此，我们推测这些特定的 lncRNAs 可能是神经胶质瘤的潜在生物标志物和治疗靶点。
